C
Core Diagnostics
Clinical laboratory focused on Next Generation Diagnostics for disease stratification and therapy selection
About Core Diagnostics
CORE Diagnostics operates in the healthcare sector, specializing in advanced diagnostic solutions for hereditary and sporadic cancers, kidney diseases, and reproductive health. The company serves a diverse clientele, including hospitals, research centers, and individual patients. CORE Diagnostics leverages cutting-edge technologies such as liquid biopsies, ddPCR, PCR, rtPCR, qPCR, NGS, and Sanger Sequencing to provide precise and early diagnosis. The business model revolves around offering high-quality diagnostic tests and services, which are trusted by over 3,000 doctors and have impacted 170,000 patient lives. Revenue is generated through partnerships with pharmaceutical companies, healthcare institutions, and direct patient services. The company is based in Gurgaon, Haryana, and is recognized for its comprehensive biopsy reports and automated cytogenetics and cytopathology platforms. CORE Diagnostics aims to enhance diagnostic confidence and reduce the need for retesting by providing detailed images and adhering to global reporting guidelines.
Source: Dealroom company dataAt a glance
- Founded
- 2012
- Headquarters
- Gurgaon, India
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Artiman Ventures
Eight Roads Ventures
F-Prime
InnoVen Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Core Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Core Diagnostics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.